Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 26 studies | 39% ± 14% | |
| astrocyte | 18 studies | 39% ± 18% | |
| oligodendrocyte | 16 studies | 36% ± 15% | |
| macrophage | 15 studies | 41% ± 20% | |
| fibroblast | 15 studies | 31% ± 13% | |
| oligodendrocyte precursor cell | 14 studies | 41% ± 19% | |
| microglial cell | 14 studies | 51% ± 14% | |
| glutamatergic neuron | 12 studies | 56% ± 23% | |
| pericyte | 11 studies | 33% ± 15% | |
| GABAergic neuron | 10 studies | 56% ± 20% | |
| endothelial cell of lymphatic vessel | 9 studies | 39% ± 16% | |
| B cell | 9 studies | 29% ± 13% | |
| epithelial cell | 9 studies | 37% ± 15% | |
| adipocyte | 9 studies | 44% ± 12% | |
| mast cell | 9 studies | 34% ± 13% | |
| ciliated cell | 9 studies | 32% ± 15% | |
| smooth muscle cell | 8 studies | 28% ± 10% | |
| myeloid cell | 8 studies | 38% ± 15% | |
| neuron | 7 studies | 49% ± 21% | |
| interneuron | 7 studies | 58% ± 22% | |
| dendritic cell | 7 studies | 46% ± 12% | |
| retinal ganglion cell | 6 studies | 27% ± 11% | |
| retina horizontal cell | 6 studies | 32% ± 12% | |
| monocyte | 6 studies | 45% ± 13% | |
| type II pneumocyte | 6 studies | 37% ± 11% | |
| classical monocyte | 5 studies | 24% ± 6% | |
| amacrine cell | 5 studies | 36% ± 7% | |
| retinal cone cell | 5 studies | 26% ± 6% | |
| cardiac muscle cell | 5 studies | 30% ± 7% | |
| lymphocyte | 5 studies | 31% ± 13% | |
| T cell | 5 studies | 35% ± 8% | |
| natural killer cell | 5 studies | 28% ± 8% | |
| club cell | 5 studies | 34% ± 13% | |
| type I pneumocyte | 5 studies | 34% ± 8% | |
| basal cell | 5 studies | 33% ± 18% | |
| granule cell | 4 studies | 45% ± 7% | |
| plasma cell | 4 studies | 30% ± 8% | |
| retinal bipolar neuron | 4 studies | 27% ± 10% | |
| retinal pigment epithelial cell | 4 studies | 37% ± 19% | |
| CD4-positive, alpha-beta T cell | 4 studies | 24% ± 5% | |
| CD8-positive, alpha-beta T cell | 4 studies | 22% ± 5% | |
| endothelial cell of artery | 4 studies | 23% ± 6% | |
| mesothelial cell | 4 studies | 31% ± 10% | |
| vein endothelial cell | 4 studies | 33% ± 19% | |
| Mueller cell | 4 studies | 37% ± 5% | |
| retinal rod cell | 4 studies | 32% ± 6% | |
| capillary endothelial cell | 4 studies | 25% ± 8% | |
| endothelial cell of vascular tree | 4 studies | 36% ± 19% | |
| CD16-negative, CD56-bright natural killer cell, human | 3 studies | 24% ± 6% | |
| hematopoietic precursor cell | 3 studies | 32% ± 15% | |
| non-classical monocyte | 3 studies | 29% ± 9% | |
| GABAergic interneuron | 3 studies | 48% ± 4% | |
| glial cell | 3 studies | 33% ± 7% | |
| progenitor cell | 3 studies | 34% ± 7% | |
| effector memory CD8-positive, alpha-beta T cell | 3 studies | 25% ± 6% | |
| mononuclear phagocyte | 3 studies | 36% ± 11% | |
| GABAergic amacrine cell | 3 studies | 42% ± 4% | |
| ON-bipolar cell | 3 studies | 31% ± 10% | |
| glycinergic amacrine cell | 3 studies | 44% ± 6% | |
| rod bipolar cell | 3 studies | 32% ± 9% | |
| hepatocyte | 3 studies | 44% ± 14% | |
| abnormal cell | 3 studies | 33% ± 22% | |
| neural progenitor cell | 3 studies | 38% ± 12% | |
| connective tissue cell | 3 studies | 30% ± 12% | |
| ependymal cell | 3 studies | 50% ± 16% | |
| myofibroblast cell | 3 studies | 33% ± 12% | |
| alveolar macrophage | 3 studies | 51% ± 11% | |
| respiratory goblet cell | 3 studies | 38% ± 17% | |
| muscle cell | 3 studies | 35% ± 23% | |
| goblet cell | 3 studies | 40% ± 29% | |
| transit amplifying cell | 3 studies | 36% ± 26% | |
| mural cell | 3 studies | 41% ± 13% | |
| mucus secreting cell | 3 studies | 33% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 1720.90 | 1443 / 1445 | 100% | 20.54 | 183 / 183 |
| lung | 100% | 2153.96 | 578 / 578 | 99% | 14.39 | 1145 / 1155 |
| intestine | 100% | 1758.68 | 966 / 966 | 98% | 10.42 | 518 / 527 |
| stomach | 100% | 1288.32 | 358 / 359 | 98% | 12.24 | 281 / 286 |
| brain | 99% | 1783.69 | 2603 / 2642 | 98% | 19.06 | 692 / 705 |
| breast | 100% | 2036.21 | 459 / 459 | 96% | 16.36 | 1077 / 1118 |
| ovary | 100% | 2785.36 | 180 / 180 | 95% | 11.13 | 410 / 430 |
| bladder | 100% | 1782.43 | 21 / 21 | 94% | 10.28 | 473 / 504 |
| skin | 100% | 2022.92 | 1808 / 1809 | 94% | 13.87 | 442 / 472 |
| uterus | 100% | 2622.06 | 170 / 170 | 93% | 11.32 | 429 / 459 |
| pancreas | 99% | 870.79 | 324 / 328 | 94% | 9.97 | 167 / 178 |
| thymus | 100% | 1886.52 | 653 / 653 | 91% | 11.54 | 550 / 605 |
| prostate | 100% | 1368.01 | 245 / 245 | 89% | 10.26 | 446 / 502 |
| kidney | 100% | 1020.33 | 89 / 89 | 87% | 9.65 | 786 / 901 |
| adrenal gland | 100% | 1522.36 | 258 / 258 | 85% | 8.63 | 195 / 230 |
| liver | 95% | 645.75 | 214 / 226 | 66% | 4.65 | 267 / 406 |
| blood vessel | 100% | 2076.33 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| spleen | 100% | 1545.07 | 241 / 241 | 0% | 0 | 0 / 0 |
| adipose | 100% | 2167.96 | 1203 / 1204 | 0% | 0 | 0 / 0 |
| muscle | 100% | 1654.06 | 802 / 803 | 0% | 0 | 0 / 0 |
| heart | 94% | 1120.45 | 810 / 861 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 89% | 10.80 | 40 / 45 |
| peripheral blood | 85% | 1072.28 | 786 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 79% | 8.24 | 63 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 76% | 7.50 | 22 / 29 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0007605 | Biological process | sensory perception of sound |
| GO_0016567 | Biological process | protein ubiquitination |
| GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
| GO_0042981 | Biological process | regulation of apoptotic process |
| GO_0036211 | Biological process | protein modification process |
| GO_0005730 | Cellular component | nucleolus |
| GO_0000151 | Cellular component | ubiquitin ligase complex |
| GO_0005694 | Cellular component | chromosome |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0016274 | Molecular function | protein-arginine N-methyltransferase activity |
| GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0008270 | Molecular function | zinc ion binding |
| Gene name | FBXO11 |
| Protein name | Alternative protein FBXO11 F-box only protein 11 (Protein arginine N-methyltransferase 9) (Vitiligo-associated protein 1) (VIT-1) F-box protein 11, isoform CRA_f (cDNA FLJ40415 fis, clone TESTI2038104, highly similar to F-box only protein 11) F-box protein 11 |
| Synonyms | VIT1 UG063H01 PRMT9 hCG_1987171 FBX11 |
| Description | FUNCTION: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as DTL/CDT2, BCL6 and PRDM1/BLIMP1. The SCF(FBXO11) complex mediates ubiquitination and degradation of BCL6, thereby playing a role in the germinal center B-cells terminal differentiation toward memory B-cells and plasma cells. The SCF(FBXO11) complex also mediates ubiquitination and degradation of DTL, an important step for the regulation of TGF-beta signaling, cell migration and the timing of the cell-cycle progression and exit. Binds to and neddylates phosphorylated p53/TP53, inhibiting its transcriptional activity. Plays a role in the regulatiom of erythropoiesis but not myelopoiesis or megakaryopoiesis. Mechanistically, activates erythroid genes by mediating the degradation of BAHD1, a heterochromatin-associated protein that recruits corepressors to H3K27me3 marks . Participates in macrophage cell death and inflammation in response to bacterial toxins by regulating the expression of complement 5a receptor 1/C5AR1 and IL-1beta . Acts as a critical regulator to determine the level of MHC-II by mediating the recognition of degron at the P/S/T domain of CIITA leading to its ubiquitination and subsequent degradation via the proteasome . Participates in the antiviral repsonse by initiating the activation of TBK1-IRF3-IFN-I axis. Mediates the 'Lys-63'-linked ubiquitination of TRAF3 to strengthen the interaction between TRAF3 and TBK1 . . |
| Accessions | A0A804HK63 H0YAV3 L8E8F1 E7EP88 ENST00000402508.5 [Q86XK2-6] Q86XK2 ENST00000493962.6 ENST00000434234.5 ENST00000403359.8 [Q86XK2-1] ENST00000405808.5 C9IYF0 ENST00000683894.1 B3KUR1 ENST00000424163.2 B5MCV6 |